Resveratrol Cancer Research Results

RES, Resveratrol: Click to Expand ⟱
Features: polyphenol
Found in red grapes and products made with grapes.
Resveratrol is a polyphenol compound found in various plant species, including grapes, berries, and peanuts.
• Anti-inflammatory effects, Antioxidant effects:
- Antiplatelet aggregation for stroke prevention
- BioAvialability use piperine
- some sources may use Japanese knotweed roots (Reynoutria Japonica - root) as source which might contain Emodin (laxative)
-known as Nrf2 activator, both in cancer and normal cells. Which raises controversity of use in ROS↑ therapies. Interestingly there are reports of NRF2↑ and ROS↑ in cancer cells. This raises the question of if it is a chemosensitizer. However other reports indicate NRF2 droping with Res, indicating it maybe a chemosenstizer.
- RES is also considered to be them most effective natural SIRT1↑ -activating compound (STACs).

However, in the presence of certain metals, such as copper or iron, resveratrol can undergo a process called Fenton reaction, which can lead to the generation of reactive oxygen species (ROS). The pro-oxidant effects of resveratrol are often observed at high concentrations, typically above 50-100 μM, and in the presence of certain metals or other pro-oxidant agents. In contrast, the antioxidant effects of resveratrol are typically observed at lower concentrations, typically below 10-20 μM.

Clinical trials have used doses ranging from 150 mg to 5 grams per day. Lower doses (< 1 g/day) are often well-tolerated, but higher doses might be necessary for therapeutic effects and can be associated with side effects.

-Note half-life 1-3 hrs?.
BioAv poor: min 5uM/L required for chemopreventive effects, but 25mg Oral only yeilds 20nM. co-administration of piperine
Pathways:
- usually induce ROS production in cancer cells, while reducing ROS in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓,
- Lowers AntiOxidant defense in Cancer Cells: NRF2(typically increased), TrxR↓**, SOD↓, GSH↓ Catalase↓ HO1↓(wrong direction), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, TIMP2, IGF-1↓, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, CK2↓, Hh↓, CD133↓, CD24↓, β-catenin↓, sox2↓, notch2↓, nestin↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 Reactive oxygen species (ROS) ↑ ROS (dose- & context-dependent) ↓ ROS / buffered Conditional Driver Biphasic redox modulation Resveratrol can act as a pro-oxidant in cancer cells while functioning as an antioxidant in normal cells
2 Mitochondrial integrity / intrinsic apoptosis ↓ ΔΨm; ↑ caspase activation ↔ preserved Driver Execution of intrinsic apoptosis Mitochondrial dysfunction and apoptosis follow ROS elevation in cancer cells
3 SIRT1 / AMPK axis ↑ AMPK; context-dependent SIRT1 modulation ↑ SIRT1 / ↑ AMPK Driver Metabolic stress signaling Resveratrol modulates energy-sensing pathways affecting survival and metabolism
4 PI3K → AKT → mTOR axis ↓ AKT / ↓ mTOR ↔ adaptive suppression Secondary Growth and anabolic inhibition Downregulation of growth signaling contributes to cytostasis and apoptosis sensitization
5 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Secondary Suppression of survival and inflammatory transcription NF-κB inhibition contributes to reduced proliferation and invasion
6 Cell cycle regulation ↑ G1/S or G2/M arrest ↔ largely spared Phenotypic Cytostatic growth control Cell-cycle arrest reflects upstream signaling disruption
7 HIF-1α / VEGF axis ↓ HIF-1α; ↓ VEGF ↔ minimal Secondary Anti-angiogenic pressure Interference with hypoxia-driven adaptation and angiogenesis


Scientific Papers found: Click to Expand⟱
2329- RES,    Resveratrol induces apoptosis in human melanoma cell through negatively regulating Erk/PKM2/Bcl-2 axis
- in-vitro, Melanoma, A375
P53↑, Bcl-2↓, BAX↑, Cyt‑c↑, ERK↓, PKM2↓, Apoptosis↑, γH2AX↑, Casp3↑, cl‑PARP1↑,
2328- RES,    Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin
- in-vitro, Cerv, HeLa - in-vitro, Liver, HepG2 - in-vitro, BC, MCF7
PKM2↓, mTOR↓, GlucoseCon↓, lactateProd↓,
105- RES,  QC,    The Effect of Resveratrol and Quercetin on Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem Cell
- in-vitro, Pca, PANC1
N-cadherin↓, TNF-α↓, ACTA2↓, EMT↓, CD133↓, CSCs↓,
871- RES,  CUR,  QC,    The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice
- in-vitro, BC, 4T1 - in-vivo, BC, 4T1
T-Cell↑, Neut↓, Macrophages↓, ROS↑, MMP↓, other↓, AntiTum↑, TumVol↓,
1511- RES,  Chemo,    Combination therapy in combating cancer
- Review, Var, NA
eff↑, *NRF2↑, *GSH↑, *ROS↓, chemoPv↑, ChemoSideEff↓,
1506- RES,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, Var, NA
DNMTs↓, BRCA1↑, HDAC↓, SIRT1↑, p300↓, survivin↓, HDAC1↓, HDAC3↓, HDAC8↓,
1492- RES,    Resveratrol: Biological and pharmaceutical properties as anticancer molecule
- Review, Var, NA
RadioS↑, ChemoSen↑,
1491- RES,  doxoR,  Cisplatin,    Resveratrol Augments Doxorubicin and Cisplatin Chemotherapy: A Novel Therapeutic Strategy
- in-vivo, Var, NA
RadioS↑, ChemoSen↑,
1490- RES,    Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues
- Review, Var, NA
TumCCA↑, ROS↑, Ca+2↑, MMP↓, ATP↓, TOP1?, P53↑, p53 Wildtype∅, Akt↓, mTOR↓, EMT↓, *BioAv↓,
2439- RES,    By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice
- in-vitro, HCC, HCCLM3 - in-vitro, Nor, L02 - in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, Bel-7402 - in-vitro, HCC, HUH7
HK2↓, ChemoSen↑, other↑, Glycolysis↓, lactateProd↓, TumCP↓, Casp3↑, cl‑PARP↑, PKM2↓,
1391- RES,  BBR,    Effects of Resveratrol, Berberine and Their Combinations on Reactive Oxygen Species, Survival and Apoptosis in Human Squamous Carcinoma (SCC-25) Cells
- in-vitro, Tong, SCC25
ROS↑, Synergy↑,
1282- RES,    Resveratrol Inhibits CD4+ T Cell Activation by Enhancing the Expression and Activity of Sirt1
- vitro+vivo, Var, NA
T-Cell↓, SIRT1↑, CD4+↓,
1047- RES,    Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells
- in-vitro, Lung, H1299 - in-vitro, Lung, A549 - in-vitro, Lung, H460
PD-L1↑, Snail↑, E-cadherin↓, N-cadherin↑, Fibronectin↑, Vim↑, Axin2↓,
993- RES,    Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells
- in-vitro, CRC, Caco-2 - in-vivo, Nor, HCEC 1CT
TumCG↓, Glycolysis↓, PPP↓, ATP↑, PDH↑, Ca+2↝, TumCP↓, lactateProd↓, OCR↑, ECAR↓, *ECAR∅, *other?, cycE/CCNE↑, cycA1/CCNA1↑, TumCCA↑, cycD1/CCND1↑, OXPHOS↑,
967- RES,    Resveratrol binds and inhibits transcription factor HIF-1α in pancreatic cancer
- Analysis, PC, NA
Hif1a↓,
924- RES,    Resveratrol sequentially induces replication and oxidative stresses to drive p53-CXCR2 mediated cellular senescence in cancer cells
- in-vitro, OS, U2OS - in-vitro, Lung, A549
TumCCA↑, ROS↑, γH2AX↑, ATM↑, p‑CHK1↑, cellSen↑, CXCR2↑,
885- RES,    Resveratrol induces intracellular Ca2 + rise via T-type Ca2 + channels in a mesothelioma cell line
- in-vitro, RCC, REN - in-vitro, Nor, MeT5A
TumCG↓, Ca+2↑, *toxicity↓,
884- RES,  PTS,    Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving the Downregulation of HPV Oncoprotein E6 in Cervical Cancer Cells
- in-vitro, Cerv, HeLa
TumCD↑, TumCCA↑, E6↓, Casp3↑, P53↑,
883- RES,    Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
- Review, Var, NA
HDAC↓, TumCCA↑, Apoptosis↑, angioG↓, ROS↑,
882- RES,    Resveratrol: A Double-Edged Sword in Health Benefits
- Review, Var, NA
AntiTum↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, Bcl-xL↓, P53↑, NAF1↓, NRF2↑, ROS↑, Apoptosis↑, HDAC↓, TumCCA↑, TumAuto↑, angioG↓, iNOS↓,
881- RES,    Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein
- in-vitro, BC, MDA-MB-231 - in-vitro, PC, PANC1 - in-vitro, Pca, DU145
TumCCA↑, cycD1/CCND1↓, Bcl-xL↓, Mcl-1↓, other↓,
880- RES,    Forkhead Proteins Are Critical for Bone Morphogenetic Protein-2 Regulation and Anti-tumor Activity of Resveratrol
- in-vitro, BC, MDA-MB-231
other↓, TumW↓, FOXO↑, BMP2↑,
879- RES,    Evidence that TNF-β induces proliferation in colorectal cancer cells and resveratrol can down-modulate it
- in-vitro, CRC, HCT116
TumCP↓, NF-kB↓,
878- RES,    Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression
- vitro+vivo, CRC, LoVo
TumMeta↓, E-cadherin↑, Vim↓, TGF-β↓, SMAD2↓, EMT↓, SMAD3↓,
2981- RES,    Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways
- in-vitro, Colon, HT-29 - in-vitro, Colon, SW48
TumCCA↑, p27/CDKN1B↑, cycD1/CCND1↓, TumCP↓, IGF-1R↓, Akt↓, Wnt↓, P53↑, Apoptosis↑, Sp1/3/4↓, cl‑PARP↑, β-catenin/ZEB1↓, MDM2↓,
3055- RES,    Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
BioAv↓, BioAv↓, Dose↑, eff↑, eff↑, Dose↑, BioAv↑, ROS↑, MMP↓, P21↑, p27/CDKN1B↑, TumCCA↑, ChemoSen↑, COX2/PTGS2↓, 5LO↓, VEGF↓, IL1↓, IL6↓, IL8↓, AR↓, PSA↓, MAPK↓, Hif1a↓, Glycolysis↓, miR-21↓, PTEN↑, Half-Life↝, *IGF-1↓, *IGFBP3↑, Half-Life↓,
3054- RES,    Resveratrol induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis, and cell cycle arrest in the A375SM malignant melanoma cell line
- in-vitro, Melanoma, A375
TumCG↓, P21↑, p27/CDKN1B↑, CycB/CCNB1↓, ROS↑, ER Stress↑, p‑p38↑, P53↑, p‑eIF2α↑, EP4/PTGER4↑, CHOP/DDIT3↑, Bcl-2↓, BAX↓, TumCCA↑, NRF2↓, ChemoSen↑, GSH↓,
3053- RES,    Resveratrol represses estrogen-induced mammary carcinogenesis through NRF2-UGT1A8-estrogen metabolic axis activation
- in-vitro, BC, NA
NRF2↑, DNAdam↓,
3052- RES,    Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways
- in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, Bxpc-3
NAF1↓, ROS↑, NRF2↑, ChemoSen↑, TumCG↓,
2991- RES,  Chemo,    Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells
- in-vitro, Melanoma, MSTO-211H - in-vitro, Nor, MeT5A
Synergy↑, selectivity↑, Sp1/3/4↓,
2990- RES,    Resveratrol reduces cerebral edema through inhibition of de novo SUR1 expression induced after focal ischemia
- in-vivo, Stroke, NA
*OS↑, *antiOx↑, Sp1/3/4↓,
2989- RES,    Resveratrol Represses Pokemon Expression in Human Glioma Cells
- in-vitro, GBM, NA
FBI-1↓, Sp1/3/4↓,
2988- RES,    The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation
- in-vitro, HCC, HUH7
TumCMig↓, TumCI↓, uPA↓, Sp1/3/4↓,
2987- RES,    Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1
- in-vivo, Nor, NA
*VEGF↑, *iNOS↑, *NF-kB↑, *Sp1/3/4↑, *cardioP↑,
2986- RES,    Effect of the natural compound trans‑resveratrol on human MCM4 gene transcription
- in-vitro, Cerv, HeLa - in-vitro, AML, HL-60
Sp1/3/4↑,
2985- RES,    Resveratrol Inhibits Diabetic-Induced Müller Cells Apoptosis through MicroRNA-29b/Specificity Protein 1 Pathway
- in-vivo, Nor, NA - vitro+vivo, Diabetic, NA
*Sp1/3/4↓, *miR-29b↑,
2984- RES,    Involvement of miR-539-5p in the inhibition of de novo lipogenesis induced by resveratrol in white adipose tissue
- in-vivo, Nor, NA
*Sp1/3/4↓, *SREBP1/SREBF1↓, *FASN↓,
2983- RES,    Resveratrol Improves Diabetic Retinopathy via Regulating MicroRNA-29b/Specificity Protein 1/Apoptosis Pathway by Enhancing Autophagy
- in-vitro, Nor, NA
*Beclin-1/ATG6↑, *p62↓, *Sp1/3/4↓, *Apoptosis↓,
2982- RES,    The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1
- in-vitro, Melanoma, MSTO-211H
tumCV↓, Apoptosis↑, Sp1/3/4↓, p27/CDKN1B↓, P21↓, cycD1/CCND1↓, Mcl-1↓, survivin↓,
2440- RES,    Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway
- in-vitro, Lung, H460 - in-vivo, Lung, NA - in-vitro, Lung, H1650 - in-vitro, Lung, HCC827
AntiTum↑, Glycolysis↓, HK2↓, EGFR↓, Akt↓, ERK↓, GlucoseCon↓, lactateProd↓, TumCG↓, Ki-67↓,
2565- RES,    https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06788.x
- in-vivo, Nor, NA - in-vivo, NA, NA
*AntiAg↑, *TXA2↑, *PKCδ↑, *Dose↝,
2441- RES,    Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions
- Review, Var, NA
*toxicity↓, *BioAv↝, *Dose↝, *hepatoP↑, *neuroP↑, *AntiAg↑, *COX2/PTGS2↓, *antiOx↑, *ROS↓, *ROS↑, PI3K↓, Akt↓, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, NRF2↑, GPx↑, HO-1↑, BioEnh?, PTEN↑, ChemoSen↑, eff↑, mt-ROS↑, Warburg↓, Glycolysis↓, GlucoseCon↓, GLUT1↓, lactateProd↓, HK2↓, EGFR↓, cMyc↓, ROS↝, MMPs↓, MMP7↓, survivin↓, TumCP↓, TumCMig↓, TumCI↓,
2442- RES,    High absorption but very low bioavailability of oral resveratrol in humans
- in-vitro, Nor, NA
BioAv↝, Half-Life↝, BioAv↓, eff↝,
2443- RES,    Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review
- Review, Var, NA
*antiOx↑, *ROS↓, *PTEN↑, *Akt↓, *Catalase↑, *SOD↑, *ERK↓, *GSH↑, *AMPK↑, *FOXO1↝, *RNS↓, *Catalase↑, *cardioP↑, *PI3K↑, *eNOS↑, hepatoP↑,
2467- RES,    Resveratrol inhibits Ca2+ signals and aggregation of platelets
- in-vitro, Nor, NA
*AntiAg↑, Ca+2↓,
2471- RES,    Resveratrol Regulates Glucose and Lipid Metabolism in Diabetic Rats by Inhibition of PDK1/AKT Phosphorylation and HIF-1α Expression
- in-vivo, Diabetic, NA
*p‑PDK1 / PDPK1↓, *p‑Akt↓, *Hif1a↓, *GLUT1↓,
2472- RES,    Resveratrol Restores Sirtuin 1 (SIRT1) Activity and Pyruvate Dehydrogenase Kinase 1 (PDK1) Expression after Hemorrhagic Injury in a Rat Model
- in-vivo, Nor, NA
*SIRT1↑, *PGC-1α↑, *cMyc↑, *PDK1 / PDPK1↓,
2564- RES,    Effect of resveratrol on platelet aggregation by fibrinogen protection
- in-vitro, Nor, NA
*AntiAg↑, *antiOx↓, *COX2/PTGS2↓,
2687- RES,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, NA, NA - Review, AD, NA
NF-kB↓, P450↓, COX2/PTGS2↓, Hif1a↓, VEGF↓, *SIRT1↑, SIRT1↓, SIRT2↓, ChemoSen⇅, cardioP↑, *memory↑, *angioG↑, *neuroP↑, STAT3↓, CSCs↓, RadioS↑, Nestin↓, Nanog↓, TP53↑, P21↑, CXCR4↓, *BioAv↓, EMT↓, Vim↓, Slug↓, E-cadherin↑, AMPK↑, MDR1↓, DNAdam↑, TOP2↓, PTEN↑, Akt↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MALAT1↓, TCF↓, ALDH↓, CD44↓, Shh↓, IL6↓, VEGF↓, Synergy↑, HK2↓, ROS↑, MMP↓,
2566- RES,    A comprehensive review on the neuroprotective potential of resveratrol in ischemic stroke
- Review, Stroke, NA
*neuroP↑, *NRF2↑, *SIRT1↑, *PGC-1α↑, *FOXO↑, *HO-1↑, *NQO1↑, *ROS↓, *BP↓, *BioAv↓, *Half-Life↝, *AMPK↑, *GSK‐3β↓, *eff↑, *AntiAg↑, *BBB↓, *Inflam↓, *MPO↓, *TLR4↓, *NF-kB↓, *p65↓, *MMP9↓, *TNF-α↓, *IL1β↓, *PPARγ↑, *MMP↑, *ATP↑, *Cyt‑c∅, *mt-lipid-P↓, *H2O2↓, *HSP70/HSPA5↝, *Mets↝, *eff↑, *eff↑, *motorD↑, *MDA↓, *NADH:NAD↑, eff↑, eff↑,

Showing Research Papers: 101 to 150 of 180
Prev Page 3 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 180

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↓, 1,   Catalase↑, 1,   GPx↑, 2,   GPx4↓, 1,   GSH↓, 1,   GSH↑, 2,   GSR↑, 1,   GSTs↑, 1,   H2O2↑, 1,   HO-1↓, 1,   HO-1↑, 3,   lipid-P↓, 2,   lipid-P↑, 1,   NRF2↓, 1,   NRF2↑, 8,   Prx↓, 1,   ROS↓, 4,   ROS↑, 28,   ROS⇅, 2,   ROS↝, 1,   mt-ROS↑, 1,   SOD↑, 3,   SOD2↓, 1,   TAC?, 1,   TAC↑, 1,   TKT↝, 1,   Trx↓, 1,   Trx1↓, 1,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MKP5↑, 1,   OCR↑, 1,   OXPHOS↓, 1,   OXPHOS↑, 1,   PDH↑, 2,   SIRT3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 1,   AMPK↑, 4,   ATP↓, 2,   ATP↑, 1,   CRM↑, 1,   ECAR↓, 1,   FASN↑, 1,   FBI-1↓, 1,   FDG↓, 1,   G6PD↓, 1,   glucose↓, 1,   GlucoseCon↓, 6,   glut↓, 1,   GlutMet↓, 1,   GlutMet↑, 1,   Glycolysis↓, 6,   GSK‐3β↑, 2,   GSK‐3β↝, 2,   p‑GSK‐3β↓, 1,   HK2↓, 6,   lactateProd↓, 7,   NADPH↑, 1,   PFK↓, 2,   PFK1↓, 2,   PKM2↓, 7,   PPP↓, 1,   R5P↝, 1,   SIRT1↓, 1,   SIRT1↑, 12,   SIRT2↓, 1,   TCA↑, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 19,   BAX↓, 1,   BAX↑, 7,   Bcl-2↓, 9,   Bcl-xL↓, 3,   BIM↑, 1,   BNIP3↑, 1,   Casp3↑, 8,   cl‑Casp3↑, 1,   Casp9↑, 4,   Cyt‑c↑, 4,   Diablo↑, 1,   DR5↑, 2,   FasL↓, 1,   Ferroptosis↑, 1,   iNOS↓, 1,   Mcl-1↓, 2,   MDM2↓, 1,   necrosis↑, 1,   p38↓, 1,   p38↑, 1,   p‑p38↑, 2,   PUMA↑, 1,   survivin↓, 8,   TumCD↑, 1,   XIAP↓, 2,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 15,   p‑Akt↓, 1,   CK2↓, 3,   EGFR↓, 4,   ERK↓, 3,   p‑ERK↓, 1,   HER2/EBBR2↓, 1,   IGF-1R↓, 1,   JAK↓, 1,   JAK2↓, 1,   p‑JNK↓, 2,   MAPK↓, 2,   MAPK↑, 2,   mTOR↓, 8,   PDGFR-BB↓, 1,   PI3K↓, 8,   p‑PI3K↓, 1,   PI3K/Akt↓, 1,   PTEN↑, 5,   RAS↓, 1,   Sp1/3/4↓, 8,   Sp1/3/4↑, 1,   Src↓, 1,   STAT3↓, 8,   p‑STAT3↓, 2,   STAT5↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF3↑, 1,   ATF4↑, 1,   cJun↑, 1,   cMyc↓, 7,   DNMTs↓, 2,   EZH2↓, 1,   FOXO↑, 2,   FOXO4↓, 1,   HDAC↓, 3,   HDAC1↓, 2,   HDAC3↓, 1,   HDAC8↓, 1,   miR-21↓, 1,   miR-27a-3p↓, 1,   OCT4↓, 4,   other↓, 3,   other↑, 1,   other↝, 2,   SOX2↓, 3,   SOX4↓, 1,   SOX9↑, 1,   tumCV↓, 6,   ZBTB10↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 2,   CHOP/DDIT3↑, 4,   p‑eIF2α↑, 2,   ER Stress↑, 5,   GRP78/BiP↓, 1,   GRP78/BiP↑, 2,   GRP94↑, 1,   HSP27↓, 1,   IRE1↑, 1,   PERK↑, 2,   UPR↑, 2,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1,   p62↓, 2,   p62↑, 1,   TumAuto↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   BRCA1↑, 1,   DNAdam↓, 1,   DNAdam↑, 3,   P53↑, 11,   p53 Wildtype∅, 1,   PARP↑, 1,   p‑PARP↑, 1,   cl‑PARP↑, 2,   cl‑PARP1↑, 1,   POLD1↓, 1,   RAD51↓, 1,   SIRT6↑, 1,   Telomerase↓, 1,   TOP1?, 1,   TOP2↓, 1,   TP53↑, 1,   γH2AX↑, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   CDK4↝, 1,   CDK6↓, 1,   cellSen↑, 1,   p‑CHK1↑, 1,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 9,   cycD1/CCND1↑, 1,   cycE/CCNE↑, 1,   GADD34↑, 1,   Ki-67↓, 4,   P21↓, 1,   P21↑, 5,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 5,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 2,   ALDH1A1↓, 4,   Axin2↓, 1,   BMP2↑, 1,   BMPs↑, 1,   CD133↓, 6,   CD24↓, 1,   CSCs↓, 15,   EP4/PTGER4↑, 1,   FGF↑, 1,   Gli1↓, 6,   HH↓, 7,   IGF-1↓, 2,   Ki-67↓, 4,   Nanog↓, 3,   Nestin↓, 1,   NOTCH↓, 3,   NOTCH⇅, 1,   NOTCH1↓, 1,   NOTCH2↓, 1,   NOTCH2↑, 1,   p300↓, 1,   PTCH1↓, 2,   Shh↓, 3,   Smo↓, 3,   TumCG↓, 9,   TumCP↓, 18,   Wnt↓, 8,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

ACTA2↓, 1,   Ca+2↓, 1,   Ca+2↑, 3,   Ca+2↝, 1,   E-cadherin↓, 2,   E-cadherin↑, 9,   EMT↓, 17,   FAK↓, 2,   Fibronectin↓, 1,   Fibronectin↑, 1,   GLI2↓, 1,   ITGB1↓, 1,   MALAT1↓, 3,   MMP13↓, 1,   MMP2↓, 8,   MMP3↓, 1,   MMP7↓, 2,   MMP9↓, 14,   MMPs↓, 5,   N-cadherin↓, 6,   N-cadherin↑, 1,   Rho↓, 1,   ROCK1↓, 2,   Slug↓, 3,   Smad1↓, 1,   SMAD2↓, 2,   p‑SMAD2↓, 1,   SMAD3↓, 2,   p‑SMAD3↓, 1,   Snail↓, 6,   Snail↑, 1,   talin↓, 1,   TET1↑, 2,   TGF-β↓, 3,   TIMP1↑, 2,   TIMP2↑, 2,   TIMP3↑, 1,   TumCI↓, 15,   TumCMig↓, 9,   TumMeta↓, 8,   Twist↓, 1,   TXNIP↑, 1,   uPA↓, 1,   uPAR↓, 1,   Vim?, 1,   Vim↓, 4,   Vim↑, 1,   Zeb1↓, 2,   α-SMA↓, 2,   β-catenin/ZEB1↓, 9,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   HIF-1↓, 1,   Hif1a↓, 12,   Hif1a↑, 1,   VEGF↓, 11,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 4,   MMP↓, 8,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↓, 1,   CD44↓, 6,   CD8+↑, 1,   COX2/PTGS2↓, 13,   CXCL12↓, 1,   CXCR2↑, 1,   CXCR4↓, 2,   DR4↑, 2,   FOXP3↓, 1,   HLA↑, 1,   IL1↓, 1,   IL10↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 6,   IL8↓, 2,   Inflam↓, 3,   Macrophages↓, 1,   MCP1/CCL2↓, 1,   NAF1↓, 3,   Neut↓, 1,   NF-kB↓, 16,   p‑NF-kB↓, 2,   NLRP3↓, 5,   p65↓, 1,   PD-1↓, 1,   PD-L1↑, 1,   PGE2↓, 1,   PSA↓, 2,   T-Cell↓, 1,   T-Cell↑, 2,   TCF↓, 2,   Th1 response↑, 1,   TNF-α↓, 4,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AhR↓, 1,   AhR↑, 1,   AR↓, 4,   ER-α36↑, 1,   FGF21↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 5,   BioAv↑, 3,   BioAv↝, 1,   BioEnh?, 1,   ChemoSen↑, 17,   ChemoSen⇅, 1,   Dose?, 1,   Dose↑, 2,   Dose↝, 8,   eff↓, 4,   eff↑, 9,   eff↝, 3,   Half-Life↓, 1,   Half-Life↑, 1,   Half-Life↝, 3,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 8,   selectivity↑, 1,   Synergy↑, 10,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 4,   BRCA1↑, 1,   CRP↓, 1,   E6↓, 1,   EGFR↓, 4,   EZH2↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 6,   LDH↓, 1,   PD-L1↑, 1,   PSA↓, 2,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↑, 1,   AntiTum↑, 4,   cardioP↑, 2,   chemoPv↑, 3,   ChemoSideEff↓, 1,   hepatoP↑, 1,   hepatoP↝, 1,   NKG2D↑, 1,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 367

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 23,   ARE↝, 1,   Catalase↑, 7,   GPx↑, 5,   GSH↑, 9,   GSR↑, 2,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 11,   HO-1⇅, 1,   Keap1↓, 3,   lipid-P↓, 7,   mt-lipid-P↓, 1,   MDA↓, 4,   MPO↓, 2,   NQO1↑, 3,   NRF2↑, 13,   NRF2↝, 1,   RNS↓, 1,   ROS↓, 31,   ROS↑, 1,   SOD↑, 7,   TAC↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Mets↝, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

DRP1/DNM1L↓, 5,   DRP1/DNM1L↑, 1,   FIS1↓, 6,   FIS1↑, 1,   Insulin↓, 2,   MFN1↑, 2,   MFN2↓, 1,   MFN2↑, 4,   mtDam↓, 4,   OPA1↓, 1,   OPA1↑, 3,   PGC-1α↓, 1,   PGC-1α↑, 7,   SIRT3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Acetyl-CoA↓, 1,   ALAT↓, 2,   AMPK↑, 13,   ATP↑, 3,   CRM↑, 2,   ECAR∅, 1,   FAO↑, 1,   FASN↓, 1,   G6PD↑, 1,   glucose↓, 1,   GlutMet↑, 1,   Glycolysis↓, 1,   Glycolysis↝, 2,   GSK‐3β↓, 4,   GSK‐3β↑, 1,   HK2↑, 1,   LDHA↑, 2,   LDL↓, 1,   NAD↑, 1,   NADH:NAD↑, 1,   PDK1 / PDPK1↓, 1,   p‑PDK1 / PDPK1↓, 1,   PKM2↑, 2,   SIRT1↑, 24,   SIRT2↑, 1,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 3,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 1,   Cyt‑c∅, 1,   iNOS↓, 2,   iNOS↑, 1,   p38↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   Akt↑, 1,   p‑Akt↓, 1,   p‑Akt↑, 1,   CaMKII ↓, 1,   p‑CREB↑, 2,   ERK↓, 1,   IGFR↓, 1,   mTOR↓, 1,   PI3K↑, 2,   PKA↑, 1,   PKCδ↑, 1,   PP2A↑, 4,   PTEN↑, 1,   Sp1/3/4↓, 3,   Sp1/3/4↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cMyc↑, 1,   FOXO↑, 2,   FOXO1↝, 1,   miR-155↓, 1,   miR-29b↑, 1,   other?, 3,   other↑, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↝, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   p62↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CLOCK↝, 1,   IGF-1↓, 3,   IGFBP3↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 9,   MMP3↓, 1,   MMP9↓, 5,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,   eNOS↑, 1,   Hif1a↓, 1,   NO↓, 2,   TXA2↑, 1,   VEGF↓, 1,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↓, 1,   BBB↑, 3,   GLUT1↓, 1,   MMP↑, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 5,   IL1β↓, 4,   IL6↓, 2,   Inflam↓, 21,   NF-kB↓, 8,   NF-kB↑, 1,   p‑NF-kB↓, 1,   NLRP3↓, 4,   p65↓, 1,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 3,   ADAM10↑, 6,   BDNF↑, 4,   PSD95↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 13,   BACE/β-secretase↓, 3,   tau↓, 3,   p‑tau↓, 6,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARγ↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 9,   BioAv↑, 12,   BioAv↝, 2,   BioAv∅, 1,   BioEnh↑, 1,   CompStab↑, 2,   DDS↑, 2,   Dose↓, 1,   Dose↑, 1,   Dose↝, 8,   eff↑, 6,   Half-Life↓, 2,   Half-Life↝, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 1,   BP↓, 3,   IL6↓, 2,   TMAO↓, 4,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 6,   antiAll↑, 1,   AntiCan↑, 2,   cardioP↑, 8,   chemoPv↑, 3,   cognitive↑, 9,   hepatoP↑, 5,   memory↑, 8,   motorD↑, 4,   neuroP↑, 23,   OS↑, 2,   radioP↑, 1,   RenoP↑, 2,   Strength↓, 1,   toxicity↓, 3,   toxicity↑, 1,   toxicity∅, 1,   Weight↓, 1,   Weight↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 2,  
Total Targets: 177

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:141  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page